Table 2

Memantine combination therapy (results of synthesis of data)

Analysis no. and description, trials included—code (LOCF/OC data)	Efficacy domain
	Clinical global		Cognition		Function		Behaviour + mood
	SMD/WMD (95% CI)	p Value	SMD (95% CI)	p Value	SMD/WMD (95% CI)	p Value	SMD/WMD (95% CI)	p Value
Analysis 1a: trials included in the TA217 assessment report, data presented as WMDs
MD-029 (LOCF data)	WMD=−0.140 (−0.346 to 0.066)	0.182	Data not pooled		Data not pooled		WMD=−1.715 (−5.733 to 2.302)	0.403
MD-1210 (LOCF data)	WMD=−0.140 (−0.346 to 0.066)	0.182	Data not pooled		Data not pooled		WMD=−1.715 (−5.733 to 2.302)	0.403
Analysis 1b: trials included in the TA217 assessment report, data presented as SMDs
MD-029 (LOCF data)	SMD=−0.14 (−0.33 to 0.06)	0.16	SMD=−0.16 (−0.54 to 0.23)	0.43	SMD=−0.10 (−0.28 to 0.08)	0.27	SMD=−0.13 (−0.42 to 0.17)	0.41
MD-1210 (LOCF data)	SMD=−0.14 (−0.33 to 0.06)	0.16	SMD=−0.16 (−0.54 to 0.23)	0.43	SMD=−0.10 (−0.28 to 0.08)	0.27	SMD=−0.13 (−0.42 to 0.17)	0.41
Analysis 2: trials included in the TA217 assessment report. Data from patients with mild AD excluded. Data pooled within domains (SMDs)
MD-029 (LOCF data)	SMD=−0.15 (−0.35 to 0.04)	0.12	SMD=−0.29 (−0.45 to −0.14)	0.0002	SMD=−0.13 (−0.29 to 0.03)	0.11	SMD=−0.14 (−0.42 to 0.14)	0.32
MD-12 (OC data, from Winblad et al 200711)	SMD=−0.15 (−0.35 to 0.04)	0.12	SMD=−0.29 (−0.45 to −0.14)	0.0002	SMD=−0.13 (−0.29 to 0.03)	0.11	SMD=−0.14 (−0.42 to 0.14)	0.32
Analysis 3: all trials meeting our inclusion criteria, data from patients with mild disease excluded
MD-029 (LOCF data)	SMD=−0.20 (−0.32 to −0.09)	0.0005	SMD=−0.25 (−0.36 to −0.14)	<0.00001	SMD=−0.04 (−0.21 to 0.13)	0.65	SMD=−0.17 (−0.32 to −0.03)	0.02
MD-12 (OC data, from Winblad et al 200711)
MD-5015 (LOCF data)

AD, Alzheimer's disease; LOCF, last observation carried forward; OC, observed case; SMD, standardised mean difference; WMD, weighted mean differences.